GazeHealth
GazeHealth is an emerging eyecare technology company focused on developing and commercializing innovative, interventional technologies to transform patient care.
Profile
GazeHealth develops and sells medical devices for treating glaucoma and dry eye disease.
GazeHealth is an emerging eyecare technology company focused on developing and commercializing innovative, interventional technologies to transform patient care. The company has shown resilience with a 13% year-over-year revenue growth in Q1 2026, reaching $19.7 million, driven by its Interventional Glaucoma and Interventional Dry Eye segments. GazeHealth's Interventional Glaucoma revenue grew 7% to $18.3 million, while its Interventional Dry Eye segment saw a remarkable 244% increase to $1.4 million.
The company maintains a strong gross margin of 86%, reflecting efficient operations. A recent legal victory against Alcon Inc., resulting in a $55.4 million award and ongoing royalties, underscores its intellectual property strength. However, the company remains in a competitive landscape, with ongoing litigation risks and the need to scale its newer Dry Eye segment. GazeHealth's cash position stands at $85.0 million as of March 31, 2026, with improved cash usage efficiency.
Who buys this
- Ophthalmologists and optometrists
- Hospitals and surgical centers
- Specialty eyecare clinics
- Patients with glaucoma or dry eye disease
Strengths and what to watch
Strengths
- Strong intellectual property portfolio, evidenced by recent legal victory against Alcon
- Double-digit revenue growth with 86% gross margins
- Diversified product portfolio addressing both glaucoma and dry eye markets
Watch for
- Dependence on litigation outcomes for revenue from Alcon royalties
- Competition from established players in the ophthalmology device market
- Need to scale newer Interventional Dry Eye segment beyond early adoption
Recent moves
Key Information
- Founded
- 2001
Frequently Asked Questions
What does GazeHealth specialize in?
GazeHealth develops medical devices for treating glaucoma and dry eye disease. Their products target ophthalmologists, optometrists, and eyecare clinics. The company reported $19.7 million in Q1 2026 revenue, with strong growth in both glaucoma (7%) and dry eye (244%) segments, backed by an 86% gross margin.
How fast is GazeHealth growing?
GazeHealth achieved 13% year-over-year revenue growth in Q1 2026, reaching $19.7 million. Their dry eye segment surged 244% to $1.4 million, while glaucoma treatments grew 7% to $18.3 million. The company maintains an 86% gross margin and $85 million cash position as of March 2026.
What was the outcome of GazeHealth's lawsuit against Alcon?
GazeHealth won a $55.4 million award plus ongoing royalties in its intellectual property case against Alcon. This legal victory strengthens their patent portfolio but creates some revenue dependence on litigation outcomes. The ruling highlights their innovation in glaucoma and dry eye treatment technologies.
Who uses GazeHealth's medical devices?
GazeHealth serves ophthalmologists, optometrists, hospitals, and specialty eyecare clinics. Their devices treat patients with glaucoma or dry eye disease. The company focuses on interventional technologies, with glaucoma treatments generating most revenue ($18.3M) and dry eye solutions showing rapid adoption growth ($1.4M in Q1 2026).
What are the risks for GazeHealth investors?
Key risks include dependence on Alcon lawsuit royalties, competition from established ophthalmology players, and the need to scale their newer dry eye segment. While showing 244% dry eye growth, this remains a small ($1.4M) portion of total revenue compared to their core glaucoma business.
How does GazeHealth compare to other eyecare companies?
GazeHealth competes with larger ophthalmology firms but differentiates through specialized glaucoma/dry eye devices and strong IP. Their 86% gross margins and 13% revenue growth outpace many peers, though the $1.4M dry eye segment needs scaling to match established competitors' market penetration.
Sources
- www.sightsciences.com — Q1 2026 financial results and revenue guidance
- ir.bauschhealth.com — Competitive landscape in ophthalmology
- www.unitedhealthgroup.com — Healthcare market trends
- layoffhedge.com — Industry-wide cost pressures